P2y12 inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
Frontiers in Cardiovascular Medicine · 06.07.2023 · 10
DOI: 10.3389/fcvm.2023.1197161 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 06.07.2023. Verfasst von Yanqiao Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Graduate School, Beijing University of Chinese Medicine, Beijing, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
In patients with coronary artery disease (CAD) and chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI), whether short-term dual antiplatelet therapy (DAPT) followed by P2Y 12 inhibitors confers benefits compared with standard DAPT remains unclear. This study aimed to assess the efficacy and safety of 1–3 months of DAPT followed by P2Y 12 monotherapy in patients with CAD and CKD undergoing PCI.
Methods
PubMed, Embase, and the Cochrane Library were searched to identify randomized controlled trials (RCTs) comparing the P2Y 12 inhibitor monotherapy after a 1–3 months DAPT vs. DAPT in patients with CAD and CKD after PCI. The primary outcome was the incidence of major adverse cardiovascular events (MACEs), defined as a composite of all-cause mortality, myocardial infarction, stent thrombosis, target-vessel revascularization, and stroke. The safety outcome was the major bleeding events, defined as a composite of TIMI major bleeding or Bleeding Academic Research and Consortium (BARC) type 2, 3, or 5 bleeding. The pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated with a fixed- or random-effects model depending on the heterogeneity among studies.
Results
Four RCTs including 20,468 patients (2,833 patients with CKD and 17,635 without CKD) comparing P2Y 12 inhibitor monotherapy with DAPT were included in our meta-analysis. Patients with CAD and CKD had higher risk of ischemic and bleeding events. P2Y 12 inhibitor monotherapy after 1–3 months of DAPT significantly reduced the risk of major bleeding compared to DAPT in CKD patients (RR: 0.69, 95% CI: 0.51–0.95, P = 0.02) and non-CKD patients (RR: 0.66, 95% CI: 0.49–0.89, P = 0.01). No significant difference regarding MACEs between P2Y 12 inhibitor monotherapy and DAPT was found in CKD patients (RR: 0.88, 95% CI: 0.59–1.31, P = 0.53) and non-CKD (RR: 0.91, 95% CI: 0.79–1.04, P = 0.17).
Conclusion
P2Y 12 inhibitor monotherapy after 1–3 months of DAPT was an effective strategy for lowering major bleeding complications without increasing the risk of cardiovascular events in patients with CAD and CKD undergoing PCI as compared with DAPT Systematic review registration https://www.crd.york.ac.uk/PROSPERO/ , CRD42022355228.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Graduate School, Beijing University of Chinese Medicine, Beijing, China.
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Zitieren
APA
Yu, Y., Pan, D., Bai, R., Luo, J., Tan, Y., Duan, W., & Shi, D. (2023). P2y12 inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1197161
Vancouver
Yu Y, Pan D, Bai R, Luo J, Tan Y, Duan W, et al. P2y12 inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine. 2023;10. doi:10.3389/fcvm.2023.1197161
BibTeX
@article{Yu2023,
author = {Yu, Yanqiao and Pan, Deng and Bai, Ruina and Luo, Jinwen and Tan, Yu and Duan, Wenhui and Shi, Dazhuo},
title = {P2y12 inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials},
journal = {Frontiers in Cardiovascular Medicine},
year = {2023},
volume = {10},
doi = {10.3389/fcvm.2023.1197161}
}
EUVIMED